(Q37866791)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Anders Jakobsen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

589-600

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

cites work

Biliary tract cancers.

1 reference

Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment

21 January 2018

1 reference

Systemic therapy for biliary tract cancers

21 January 2018

1 reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

21 January 2018

1 reference

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

21 January 2018

1 reference

Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report

21 January 2018

1 reference

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence

21 January 2018

1 reference

Expression of Kit and platelet-derived growth factor receptors α and β in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571)

21 January 2018

1 reference

Molecular targeted therapy of biliary tract cancer--results of the first clinical studies

21 January 2018

1 reference

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

21 January 2018

1 reference

Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer

21 January 2018

1 reference

Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.

21 January 2018

1 reference

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report

21 January 2018

1 reference

Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer

21 January 2018

1 reference

Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.

21 January 2018

1 reference

Gemcitabine, irinotecan and celecoxib in patients with biliary cancer

21 January 2018

1 reference

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers

21 January 2018

1 reference

A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors

21 January 2018

1 reference

Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites

21 January 2018

1 reference

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

Alternate endpoints for screening phase II studies.

21 January 2018

1 reference

Optimising the design of phase II oncology trials: the importance of randomisation.

21 January 2018

1 reference

Design issues of randomized phase II trials and a proposal for phase II screening trials

21 January 2018

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504326%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference